United States securities and exchange commission logo





                              June 27, 2022

       Sanjay Mehta
       Chief Financial Officer
       TERADYNE, INC
       600 Riverpark Drive
       North Reading, MA 01864

                                                        Re: TERADYNE, INC
                                                            Form 10-K for the
Fiscal Year Ended December 31, 2021
                                                            Filed February 23,
2022
                                                            File No. 001-06462

       Dear Mr. Mehta:

              We have limited our review of your filing to the financial
statements and related
       disclosures and have the following comments. In some of our comments, we
may ask you to
       provide us with information so we may better understand your disclosure.

              Please respond to these comments within ten business days by
providing the requested
       information or advise us as soon as possible when you will respond. If
you do not believe our
       comments apply to your facts and circumstances, please tell us why in
your response.

                                                        After reviewing your
response to these comments, we may have additional comments.

       Form 10-K for the Fiscal Year Ended December 31, 2021

       Risks Associated with Operating a Global Business
       We are subject to risks of operating internationally..., page 15

   1.                                                   We note your discussion
here and on page 26 of your April 3, 2022 Form 10-Q related to
                                                        inflation that it could
affect your prices, demand for your products, your profit margins.
                                                        We further note your
disclosure that your test and industrial automation businesses will be
                                                        impacted by supply
constraints, which are in turn impacted by inflation. Please update this
                                                        risk factor in future
filings if recent inflationary pressures have materially impacted your
                                                        operations. In this
regard, identify the types of inflationary pressures you are facing and
                                                        how your business has
been affected.
   2.                                                   We note your risk
factor here and throughout the filing related to supply constraints. We
                                                        further note from your
Form 8-K dated April 27, 2022 that you continue to encounter
                                                        material constraints in
most product areas and that you provide wider than normal Q2
 Sanjay Mehta
TERADYNE, INC
June 27, 2022
Page 2
         guidance range reflects those supply challenges. Specify in future
filings and in more
         detail whether these challenges have materially impacted your results
of operations or
         capital resources and quantify, to the extent possible, how your
sales, profits, and/or
         liquidity have been impacted.
3.       Please consider including disclosures in future filings to discuss
known trends or
         uncertainties resulting from mitigation efforts undertaken, if any,
from your supply chain
         disruptions. Explain whether any mitigation efforts introduce new
material risks,
         including those related to product quality, reliability, or regulatory
approval of products.
       In closing, we remind you that the company and its management are
responsible for the
accuracy and adequacy of their disclosures, notwithstanding any review,
comments, action or
absence of action by the staff.

      You may contact Tara Harkins at (202) 551-3639 or Dan Gordon, Reviewing
Accountant, at (202) 551-3486 with any questions.



FirstName LastNameSanjay Mehta                                  Sincerely,
Comapany NameTERADYNE, INC
                                                                Division of
Corporation Finance
June 27, 2022 Page 2                                            Office of Life
Sciences
FirstName LastName